TessArae (privately held by a partnership led by John W Marriott III of the Marriott hotel family) and Kindstar Diagnostics Co have signed a collaboration agreement for the development of a pan-ethnic carrier screen for the Chinese population. The assay, which will be run in Kindstar's laboratories in China, employs TessArae's targeted sequencing development platform and proprietary bioanalysis software. Financial and other terms of the agreement were not disclosed.
The agreement solidifies a development partnership that allows Kindstar to leverage TessArae's design expertise to create and market its own laboratory developed test specific to the Chinese market. TessArae's development platform combines a highly multiplexed amplification strategy with a standard Affymetrix microarray protocol. Results are delivered as genomic sequence, automatically generated and analysed by TessArae's GeneCipher algorithms.